Royal Bank Of Canada’s target price points to a potential upside of 28.04% from the stock’s current price. Impax Laboratories Inc was Upgraded by BofA/Merrill to ” Neutral” on Jun 21, 2016.
Advertisement
The Hayward, California-based company said it had a loss of 4 cents per share. Over the past five trading sessions it is -24.35%; -23.48% for the month; -20.55% for the last quarter; -27.77% for the past six-months; and -48.66% for the last 12 months. Boothbay Fund Management LLC acquired a new stake in Impax Laboratories during the first quarter valued at about $307,000. Deutsche Bank AG raised its position in Impax Laboratories by 122.8% in the fourth quarter. The company has the institutional ownership of 94.00%. Finally, Skandinaviska Enskilda Banken AB publ purchased a new position in Impax Laboratories during the fourth quarter worth approximately $8,223,000.
A number of other equities research analysts have also recently issued reports on the stock. Over the one year trading period, the stock has a high price of $66.97 and its low price is recorded at $26.28.
Impax Laboratories Inc (NASDAQ:IPXL) holds the market capitalization of $1.72B along with 73.10M outstanding shares.
While looking at the Stock’s Performance, Impax Laboratories, Inc. now shows a Weekly Performance of -24.35%, where Monthly Performance is -23.48%, Quarterly performance is -20.55%, 6 Months performance is -27.77% and yearly performance percentage is -48.66%. Goldman Sachs Group Inc. began coverage on shares of Impax Laboratories in a research report on Monday, June 6th.
WallachBeth Capital today set a target price of 30 on the company’s stock. For the stock, price target value has been calculated at $33.50 based on calls of 14 experts. The stock now has an average rating of “Hold” and a consensus target price of $37.15. Impax Laboratories Inc (NASDAQ:IPXL)’s price to free cash flow for trailing twelve months is 20.30. The firm’s 50 day moving average is $30.03 and its 200-day moving average is $32.62. The stock stands almost -51.42% off versus the 52-week high and -15.17% away from the 52-week low.
Impax Laboratories (NASDAQ:IPXL) opened at 30.59 on Tuesday. The company reported $0.21 earnings per share for the quarter, missing the analyst consensus estimate by $-0.11. The company had revenue of $173 million for the quarter, compared to the consensus estimate of $224.97 million. During the same quarter previous year, the firm earned $0.34 earnings per share. Impax Laboratories, Inc. P/E (price to earnings) ratio is 48.91 and Forward P/E ratio of 9.19. Adjusted gross margin in the second quarter 2016 decreased to 40.2%, compared to adjusted gross margin of 43.1% in the prior year period.
Advertisement
As of current trade, Impax Laboratories Inc (NASDAQ:IPXL) has shown weekly downbeat performance of -24.35%. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products.
